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Abstract Intravenous enzyme replacement therapy (ERT)
with idursulfase for Hunter syndrome has not been demon-
strated to and is not predicted to cross the blood–brain barrier.
NearlyallpublishedexperiencewithERTwithidursulfasehas
therefore been in patients without cognitive impairment
(attenuated phenotype). Little formal guidance is available
on the issues surrounding ERT in cognitively impaired
patients with the severe phenotype. An expert panel was
therefore convened to provide guidance on these issues. The
clinical experience of the panel with 66 patients suggests that
somatic improvements (e.g., reduction in liver volume,
increased mobility, and reduction in frequency of respiratory
infections) may occur in most severe patients. Cognitive
benefits have not been seen. It was agreed that, in general,
severepatientsarecandidatesfor atleasta 6–12-monthtrial of
ERT, excluding patients who are severely neurologically
impaired, those in a vegetative state, or those who have a
condition that may lead to near-term death. It is imperative
that the treating physician discuss the goals of treatment,
methods of assessment of response, and criteria for discon-
tinuation of treatment with the family before ERT is initiated.
Conclusion: The decision to initiate ERT in severe Hunter
syndrome should be made by the physician and parents and
must be based on realistic expectations of benefits and risks,
with the understanding that ERT may be withdrawn in the
absence of demonstrable benefits.
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The development of therapies for rare complex diseases,
with their associated high price, has raised many questions
and concerns related to pharmacoeconomics and societal
desires to meet the particular needs of patients with rare
diseases. Enzyme replacement therapy (ERT) has become a
standard of care for patients with several lysosomal storage
disorders [12, 15, 25, 36], but because of disease
heterogeneity, particularly in the mucopolysaccharidoses,
there is disagreement as to the role that such treatments play
for the severely affected patients as well as patients who are
at the end stages of disease.
Hunter syndrome (mucopolysaccharidosis II, OMIM
309900) is one of these mucopolysaccharidoses [17] for
which a specific, targeted treatment, ERT with idursulfase
(Elaprase®, Shire Human Genetic Therapies, Inc., Cam-
bridge, MA, USA), has been developed [25]. Approximately
two thirds of the patients with this condition will develop
progressive neurodegeneration [24], ultimately affecting
cognitive function and limiting lifespan. Intravenous admin-
istration of ERT does not allow for sufficient enzyme to
cross the blood–brain barrier and reach the central nervous
system, yet some physicians and families have seen benefits
to its use in these severe patients for the improvement or
stabilization of some somatic signs and symptoms.
The present manuscript is based on discussions of an
international panel of physicians experienced in the
management and treatment of patients with Hunter syn-
drome. This group was convened in mid-2008 by Shire
Human Genetic Therapies, Inc. (Cambridge, MA, USA) to
discuss issues surrounding the use of idursulfase in Hunter
patients with the severe phenotype. This manuscript follows
two previous papers on diagnosis and management of
Hunter syndrome that were developed in a similar fashion
[17, 26].
Hunter syndrome overview
Hunter syndrome (mucopolysaccharidosis II, MPS II) is a
rare, X-linked metabolic disease that is caused by a
deficiency of the lysosomal enzyme, iduronate-2-sulfatase
(I2S) [1, 27]. This enzyme catalyzes the removal of sulfate
at the 2 position of L-iduronic acid present at the
nonreducing end of the glycosaminoglycans (GAG)
dermatan sulfate and heparan sulfate. In Hunter syndrome
patients, these substrates accumulate both intracellularly
and extracellularly and, through poorly understood mech-
anisms, lead to the clinical features of the disease. Over 300
mutations in the gene encoding iduronate-2-sulfatase have
been described, many of which represent private or
nonrecurrent mutations. There is no evidence of significant
disease modifiers, and thus the heterogeneity of the disease
phenotype (see below) is believed to be related to the
amount and activity of residual enzyme conferred by the
mutation. As such, deletions and gene rearrangements,
which account for up to 25% of Hunter syndrome cases,
always result in a severe phenotype [10, 13, 16, 22, 32].
General phenotype
The phenotypic expression of Hunter syndrome has
recently been described in detail [17, 37]. MPS II affects
multiple organs and systems with a variable age of onset of
signs and symptoms and a variable rate of progression. The
clinical spectrum of Hunter syndrome spans a wide range,
from an attenuated to a severe phenotype [27]. Patients
usually appear normal at birth, but in the most severely
affected patients, signs and symptoms typically begin to
appear between 2 and 4 years of age. All affected patients,
including those with an attenuated phenotype, experience
progressive somatic involvement, including enlarged liver
and spleen, skeletal and joint involvement resulting in
reduced joint range of motion and contractures, and heart
and airway disease [17, 27, 37]. In addition, patients with
the severe phenotype experience profound neurological
involvement that results in severe cognitive impairment,
progressive neurodegeneration, and death in the second
decade of life [17, 41, 42]. Patients with an attenuated
phenotype demonstrate normal intelligence and usually
survive into adulthood, although shortened life span is seen
[40]. The prediction of an attenuated or severe phenotype is
difficult early in the course of the disease for many patients.
Severe Hunter syndrome
Severe Hunter syndrome is the description used to refer to
patients who demonstrate progressive central nervous
system involvement with early cognitive impairment. It
has been estimated that about two thirds of patients are
destined to have a severe phenotype [7, 24, 32]. Patients
with a severe phenotype typically have an earlier onset of
signs and symptoms—age 2 to 4 years—than is seen with
the attenuated phenotype [42]. The profound cognitive
impairment results in delayed developmental milestones,
with an onset in early childhood. Developmental skills
plateau between 4 and 6 years of age and decline thereafter.
These patients often exhibit severe behavioral problems,
including hyperactivity, obstinacy, and aggression, begin-
ning in the second year of life and continuing to late
childhood [39]. Behavior may later appear to improve, with
a decrease in hyperactivity and aggression, but this change
is due to continuing neurodegeneration [39]. Late-stage
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associated with seizures and lack of mobility [41].
Communicating hydrocephalus with increased intracranial
pressure may contribute to the behavioral problems, as well
as seizures [33, 38].
Management and treatment of severe Hunter syndrome
Historically, the management of Hunter syndrome was
directed to the specific disease symptoms and complica-
tions, regardless of the phenotype [23, 24]. For example,
surgery may be required to relieve respiratory obstruction
caused by enlarged tonsils and adenoids. As emphasized in
a recent review, the management of Hunter syndrome is
never routine, and because of the progressive multisystem
involvement,managementalwaysrequiresamultidisciplinary
and anticipatory approach [24].
Recombinant human I2S (idursulfase, Elaprase®, Shire
Human Genetic Therapies, Inc., Cambridge, MA, USA)
was approved for the treatment of Hunter syndrome in 2006
and is available in the United States, European Union, and
other countries. Idursulfase is administered intravenously
on a weekly basis in the hospital setting. Some Hunter
syndrome patients have been reported to have received
infusions at home; this is only undertaken after a lengthy
screening process and is not available in all countries [2–4,
14, 21]. The approval of idursulfase was based on data from
the pivotal clinical trial, which demonstrated that 1 year of
weekly infusions of 0.5 mg/kg significantly improved the
primary endpoint, a composite comprising changes in
distance walked in 6 min and changes in percent-
predicted forced vital capacity (FVC) compared to placebo
[25]. Other improvements included reduction in urinary
GAG excretion, reduction in liver and spleen volume, and
improvements in absolute FVC.
No severely affected patients were included in the
pivotal trial because of their inability to perform pulmonary
function testing or the 6-min walk test, the two components
of the composite end point. Because a significant amount of
enzyme has not been demonstrated to and is not predicted
to cross the blood–brain barrier, clinical improvement of
central neurological involvement in patients with the severe
phenotype is not expected. Severely affected patients would
be expected to experience somatic improvement with
idursulfase treatment, however, but no clinical studies of
ERT in severe Hunter patients have been conducted and
only a few case reports have been published (e.g., [8, 28]).
Hematopoietic stem cell transplantation (HSCT) has
become the treatment of choice for the severe form of
mucopolysaccharidosis I (Hurler syndrome), in which
successful transplantation can preserve neurocognition,
improve some aspects of the somatic disease, and markedly
increase survival [24, 36]. There is little evidence to support
the use of HSCT in Hunter syndrome, however. To date,
only small case series have been reported. These indicate
that HSCT results in stabilization or improvement in some
somatic manifestations of Hunter syndrome, as seen with
recombinant ERT, but little or no cognitive benefit has been
demonstrated [11, 20, 29, 35].
Enzyme replacement therapy in severe Hunter
syndrome
The authors have had experience with the use of idursulfase
in 66 Hunter syndrome patients with the severe phenotype.
All of these patients, who were 2 to 24 years old,
experienced the somatic manifestations of Hunter syndrome
and demonstrated variable aspects of cognitive involve-
ment, including loss of speech, behavioral issues, and
developmental degeneration. After at least 1 year of ERT,
50 out of 66 patients experienced at least one type of
somatic improvement, such as a reduction in the frequency
of respiratory infections, a reduction in the coarseness of
facial features, improved joint range of motion, or im-
proved sleep apnea. It is the opinion of the authors that the
younger patients responded better than older patients.
Nearly all of the patients displayed a reduction in liver
volume (61 of 66). Improvements in hepatomegaly are
clinically relevant in that they may improve overall patient
comfort from symptoms such as dyspnea, early satiety, or
gastroesophageal reflux. In addition, a sustained reduction
in liver volume is a clinical biomarker that can be used to
reflect the activity of ERT. Parent-reported- and/or
physician-observed improvement in mobility was noted in
35 out of 66. None of the patients could be described as
experiencing a direct effect on cognitive function as a result
of ERT. In some cases, an improvement in behavior was
noted by the family, but this may have reflected improve-
ments in general health and quality of life resulting from
somatic improvements. Thirty-one patients experienced an
infusion reaction during treatment, which was managed by
slowing or stopping the infusion and pretreatment with an
antihistamine and/or corticosteroid prior to subsequent
infusions. Sufficient benefit to continue ERT was deter-
mined to be present in 61 out of 66 patients. In five cases,
the lack of clinical benefit resulted in the decision to
withdraw ERT.
Discussion and commentary
During the meeting of the expert panel, important clinical
and ethical issues concerning the use of ERT in severe
Hunter patients were discussed. These issues included: (1)
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initiation of ERT, (2) treatment goals, (3) assessing
response to ERT, (4) when to discontinue ERT, (5) the
development of guidelines about ERT in severe Hunter
syndrome, and (6) the role of government and health
reimbursement agencies in the determination of eligibility
for ERT in severe Hunter syndrome.
Initiation of ERT in severe Hunter syndrome
The decision to initiate ERT in a patient with severe Hunter
syndrome must be made with the disease stage in mind. If the
patient is newly diagnosed, they should be offered treatment,
even if the rate of cognitive decline or severity of their
eventual cognitive phenotype is not yet apparent. Hunter
syndrome is a progressive disease that affects multiple
systems and results in irreversible organ damage over time.
Both patients with attenuated disease (cognitively intact) and
those with severe disease (cognitively impaired) experience
many somatic signs and symptoms that can reduce quality of
life, including hepatosplenomegaly, impaired respiratory
function, sleep apnea, frequent infections, and joint pain [17,
27, 37]. Therefore, withholding a therapeutic that has the
potential to improve some of the somatic manifestations of
the disease because of an eventual cognitive decline is not
justifiable in the newly diagnosed patient.
It is the authors' opinion that all previously diagnosed,
symptomatic patients in whom there is an expectation that
ERT will alter the course of the somatic involvement are
also candidates for a trial of idursulfase treatment, even if
cognitive impairment is already evident. As with newly
diagnosed patients, the somatic signs and symptoms of the
disease may reduce the quality of life for both the patient as
well as for the caregivers; therefore, a trial of a therapeutic
that may improve some of the somatic features is justified.
A critical part of the initiation process for both newly
diagnosed patients and those who have been previously
diagnosed is to discuss treatment goals, the evaluation of
response to ERT, and the eventual discontinuation of
therapy with the family at the outset (discussed in more
detail below).
Not all patients with severe Hunter syndrome should be
considered candidates for ERT. It is the opinion of the
authors that patients who are severely neurologically
impaired (such as in a vegetative state) with subsequent
low expectation of benefit should not be considered for
ERT. What constitutes severe neurological impairment may
be the subject of some debate, but a patient who is
gastrostomy fed due to an inability to swallow would likely
fall into this category. Similarly, patients who have a
disease manifestation or other condition that may lead to
near-term death should not receive ERT.
Goals of treatment
Before beginning ERT, it is absolutely essential that the
physician and family discuss the goals of treatment,
expectations for response, methods for evaluating response,
and criteria for discontinuing therapy. This discussion
should ideally be directly between the treating physician
and family. It should be emphasized in these discussions
that ERT should be considered a trial and that the response
to ERT will be evaluated after a minimum of 6 to
12 months. A key point that must be made is that ERT
will not alter the course of the neurological decline but
may produce somatic improvements, such as improved
mobility, reductions in liver and spleen volumes, and
reductions in respiratory infections and resultant hospital-
izations. A written summary of the discussion may be
helpful in managing family expectations and could
include the statement that the response to ERT will be
e v a l u a t e da tac e r t a i nt i m ep o i n ta n dt h a tE R Tm a yb e
discontinued if the physician and family agree that no
benefit has been demonstrated. In the authors' opinion, a
perceived improvement in the quality of life by the family
should be taken into strong consideration as a reason to
continue therapy even if other clinical benefits are not
obvious on examination.
Parents and guardians need to be aware that not all
responses may be positive. For example, infusion reactions,
which typically involve pyrexia, chills, flushing, and/or
headache, would be expected to occur in some patients (as
they do in patients with an attenuated phenotype [25]), and
the patients would not be able to articulate their symptoms
during these events. It was also the experience of several
members of the panel that ERT may result in worsening of
behavioral problems in some severe Hunter patients.
The importance of a discussion with the family about
goals and expectations cannot be understated, as these
expectations play a major role in influencing their decision
about whether to initiate ERT. This was recently illustrated
in a survey study by Coman and colleagues [5]. In their
study, 249 parents/caregivers and adult patients with an
MPS disorder who were part of MPS support groups in the
United States and Australia were surveyed to solicit their
opinion of whether to initiate ERT based on a hypothetical
phenotype and hypothetical response to ERT. For Hunter
syndrome patients with a severe phenotype and with the
expectation that ERT would result in minimal physical
improvement, no change in cognitive involvement, and a 3-
year increase in expected life span, 57% of respondents
would choose to use ERT. For the same patients and same
expectations, with the exception of a 15-year increase in
lifespan, 79% of respondents would choose ERT. If
cognitive improvement were expected, nearly all would
choose ERT.
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The major challenge in evaluating the response to ERT in
severe Hunter patients is the lack of assessment tools that are
validated in this population. Forexample, there isno validated
instrument that can objectively measure changes in function
and quality of lifein cognitivelyimpairedpatientswithHunter
syndrome, although the development of such an instrument is
currently the object of much concerted effort. Additionally,
there are no validated biomarkers that can be used to measure
response to treatment, although again much research effort is
currentlydirectedtowardsthisproblem.Somephysicianshave
attempted to use clinical trial endpoints, but these were
developedforpatientswithnocognitive involvement.Patients
with cognitive impairment are most often unable to compre-
hend and cooperate with testing [9]. For example, such
patients cannot independently perform the 6-min walk test
(6MWT), and the results of a “parent-assisted” 6MWT are
not meaningful for evaluating mobility and endurance in
severely affected patients and should not be used. Similarly,
pulmonary function tests like the ones that were used to
demonstrate the clinical efficacy of idursulfase in clinical
trials require the understanding and cooperation of the patient
and are beyond the capabilities of severely affected patients.
However, certain evaluations are useful in this population.
The physician may be able to evaluate joint range-of-motion
inthecognitivelyimpairedpatientandcannoteimprovements
in liver and spleen size, coarseness of facial features, and
macroglossia on examination. Frequency of respiratory
infections and resulting hospitalizations is another factor that
may be quantified. Yet, assessing the response to ERT is for a
largepartsubjectiveandmust,bynecessity,bebaseduponthe
physician's clinical impression and upon parental assessment.
Certainly parents are inherently biased and may see
improvement where no objective improvement exists;
however, parents can report on objective milestones (e.g.,
getting out of bed, climbing stairs, improved appetite, etc.).
In the authors' opinion, an important goal of therapy is the
improvement in quality of life for the patient and family, so a
perception by the family of improved quality of life should
be taken into strong consideration when deciding whether or
not to continue therapy.
Decision to stop ERT in severe Hunter syndrome
The use of ERT in a patient with severe Hunter syndrome
should be considered a trial by both the physician and the
family. Goals for treatment shouldhavebeendiscussed before
ERT was initiated, with assessment occurring after some
agreed upon time period. It is the opinion of most of the
authorsthat6to12monthsshouldbesufficienttodetermineif
clinical benefit is occurring [37]; however, some authors feel
that up to 18 months may be needed. Included in these
discussions should be the idea that ERT cannot stop the
eventual neurological decline and should at some point be
discontinued. Although such discussions can be difficult, it is
important to convey to families that when a patient is
significantly neurologically impaired, such as being gastro-
stomy fed due to an inability to swallow or in a vegetative
state, there is little benefit to continuing with ERT. Similarly,
it is the experience of the authors that occasionally a patient
with severe Hunter syndrome will display exacerbated
behavioral difficulties as a result of therapy; such an
occurrence often reduces patient and family quality of life
and can be the criterion for discontinuing ERT.
It should be pointed out that, to some families, the goal of
ERT is to prolong survival no matter what is the state of the
patient. In certain countries (e.g., Germany, UK, and Austria),
ERT would currently be continued if the parents insisted,
despite the apparent lack of response. In certain provinces of
Canada, neurological deterioration and loss of independent
functioning could be the basis for discontinuation of treat-
ment. Comprehensive guidelines are needed to help guide
these decisions and are currently in development.
Guidelines for ERT in severe Hunter syndrome
Guidelines for the use of idursulfase in the treatment of
Hunter syndrome have been published for Australia [18]
and UK [34] and are being developed in other countries and
regions. As expected, treatment guidelines will differ
among countries. For example, in the UK, all patients with
a documented I2S deficiency are eligible to receive
idursulfase regardless of phenotype, whereas in Australia
only patients with an attenuated phenotype are considered
eligible for treatment. The Australian guidelines allow the
treatment of young patients before the phenotype can be
determined, but stipulate that ERT is to be withdrawn if
neurological involvement becomes evident. To date, guide-
lines specific to treatment of severe Hunter syndrome
patients have not been published for any other country.
Role of government and health reimbursement agencies
The policies of the local health care system may influence
the decision about which severe Hunter patients might
receive ERT. For example, in the UK all patients with
documented I2S deficiency are eligible for ERT, regardless
of phenotype [34]. Similarly, in Germany, all patients
would be offered treatment (Michael Beck, personal
communication). In Canada, the decision about ERT would
be made on a case-by-case evaluation and would depend on
the level of funding for ERT in the individual provinces.
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has a complete deletion of the gene) under the age of
5 years would likely be treated, but an older patient who
presents clear evidence of neurodegeneration would not
(Lorne Clarke, personal communication). In the United
States, the decisions are made by the individual physicians
and the patient's families or guardians. In any situation, it is
important that the ultimate decision be made jointly by the
physician and the family.
Governments and reimbursement agencies are increas-
ingly using pharmacoeconomic analyses to guide decisions
about the use and funding of new drugs or treatments. No
cost-effectiveness study of ERT in Hunter syndrome has
been published. In the cases of Fabry disease [6, 21] and
MPS VI [30], traditional analyses based on the cost per
quality-adjusted life year have failed to demonstrate cost-
effectiveness of ERT. The societal and ethical consider-
ations of funding ERT for lysosomal storage diseases have
been studied, but no consensus has emerged about methods
of funding ERT. It must be understood that these diseases
are extremely rare, and although ERT is expensive, the
overall cost to a government or reimbursement agency is
small compared with their total health care expenditures.
Summary
The decision regarding the use of ERT in Hunter
disease patients with a severe phenotype is complex
and based on many considerations, including the clinical
status of the patient, the expectation of benefit, and the
risks associated with ERT. The authors' clinical experi-
ences in treating severe Hunter patients have been
generally positive, but the decision to initiate and possibly
stop ERT needs to be individualized based on the
considerations noted above.
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Proposed Boxed Guidelines 
Guidelines for the Initiation and Discontinuation of Enzyme Replacement Therapy (ERT) in Severe Hunter Syndrome 
Goals and expectations for treatment, methods of assessing treatment response, and criteria for discontinuation should be determined 
by the physician and family together prior to starting ERT. 
Initiation of ERT 
o All newly diagnosed patients should be offered a trial of treatment except for patients who are severely neurologically impaired. 
o Symptomatic patients who have been previously diagnosed should be offered a trial of treatment if there is an expectation that ERT will 
improve or stabilize somatic signs and symptoms or improve quality of life. Evidence of cognitive involvement does not preclude a 
patient from a trial of ERT. 
o Patients who are severely neurologically impaired, such as those who have a gastrostomy tube due to an inability to swallow and/or are 
in a vegetative state, are not candidates for ERT. 
o Patients with a disease manifestation or other condition that may lead to near-term death should not receive ERT. 
Discontinuation of ERT 
o ERT should be discontinued after a trial of at least 6 to 12 months if no benefit is evident. The decision should be made by the treating 
physician and parents together.  
o A perception of improvement in quality of life by the family should be considered to be a benefit of treatment. 
o Exacerbated behavioral difficulties as a result of ERT should be a consideration for discontinuation. 
o When neurological decline has progressed to a severe degree (e.g., patient is gastrostomy fed due to an inability to swallow and/or in a 
vegetative state), discontinuation should be considered. 
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